PBLA — Panbela Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Panbela Presents Clinical Data On Phase 1B Clinical Trial Of Sbp-101 In Combination With Gemcitabine And NAB-Paclitaxel
Brief: Panbela Announces Positive Preclinical Data Strongly Supporting The Activity Of Sbp-101 In Ovarian Cancer Cell Lines Development Program For Sbp-101’S Expansion Into Ovarian Cancer Expected In 1H 2022
Panbela Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Panbela Posts Q3 Loss Per Share Of $0.16
Panbela Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Panbela Posts Q2 Loss Per Share Of $0.22
Panbela Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Panbela Announces Issuance Of Key U.S Patent
U.S. STOCKS ON THE MOVE-Energy cos, Barnes & Noble Education, Cuentas, Pultegroup
U.S. STOCKS ON THE MOVE-ConocoPhillips, Bed Bath & Beyond, MediWound, Virgin Galactic
Panbela Therapeutics sells more shares than planned; shares plunge
Brief: Panbela Therapeutics Announces $5.0 Million Bought Deal Offering Of Common Stock
Brief: Panbela Therapeutics Set To Join Russell Microcap Index
Brief: Panbela Presents Clinical Data On Phase 1B Clinical Trial Of Sbp-101 In Combination With Gemcitabine And NAB-Paclitaxel In Patients With Metastatic Pda At 2021 Asco Annual Meeting
Panbela Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Panbela Therapeutics Inc Reports Q1 Loss Per Share $0.23
Brief: Panbela Therapeutics Inc Files For Mixed Shelf Of Up To $100 Mln– SEC Filing
Brief: Panbela Announces Partial Clinical Hold Lifted On Phase I Polyamine Metabolic Inhibitor Study In Pancreatic Cancer
Brief: Panbela Therapeutics Reports Q4 Loss Per Share $0.09 (March 25)